| Description | Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used for the prevention and treatment of paroxysmal sleep hemoglobinuria, atypical hemolytic uremic syndrome and myasthenia gravis. |
| In vitro | Ravulizumab通过高亲和力与C5结合，阻止C5a和C5b的形成，从而避免免疫激活和溶血[1]。 |
| Synonyms | ALXN1210 |
| molecular weight | N/A |
| CAS | 1803171-55-2 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539. |